Neoadjuvant Treatment for Gastric Cancer.
- Author:
Christoph SCHUHMACHER
1
;
Daniel REIM
;
Alexander NOVOTNY
Author Information
- Publication Type:Review
- Keywords: Gastric cancer; Neoadjuvant therapy; Chemotherapy; Chemoradiotherapy; Surgery
- MeSH: Asia; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Europe; Humans; Neoadjuvant Therapy; North America; Prognosis; Recurrence; Stomach Neoplasms
- From:Journal of Gastric Cancer 2013;13(2):73-78
- CountryRepublic of Korea
- Language:English
- Abstract: Surgery is still considered to be the mainstay for the treatment of localized gastric cancer with negative margins (R0-resection) and an adequate lymph-node-dissection (D2-lymphadenectomy). Unfortunately, most cases of gastric cancer are only diagnosed at an advanced stage due to frequent recurrences after primary resection in curative intent. In order to improve prognosis after curative resection, in the recent past, patients with locally advanced tumors were subjected to a pre-, peri-, or postoperative treatment. Interestingly, postoperative chemotherapy has significantly improved survival after gastric resection in Asia, adjuvant radiochemotherapy is favored in North America and perioperative chemotherapy is considered as a treatment of choice in Europe indicating region specific approach towards the treatment. Recently there has also been growing evidence of positive outcomes of neoadjuvant radiochemotherapy on patient survival. In the present article, we discuss the concepts of neoadjuvant treatment approach and provide recommendations to surgeons based on current evidence.
